15:28 EST Monday, Dec 17, 2007

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 17, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that its Annual General Meeting of shareholders was held in Vancouver, British Columbia on December 14, 2007 at which:

- the incumbent directors of the Company, being Terrance Owen, Peter Chen, Linda Allison, Ronald Zokol, Eugene Hodgson and William McCoy were re-elected as directors of ALDA for the coming year;

- HLB Cinnamon Jang Willoughby, Chartered Accountants, were appointed auditors of ALDA for the coming year and

- in accordance with the policies of the TSX Venture Exchange, the Company's rolling 2003 Incentive Stock Option Plan was ratified for the coming year.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.

FOR FURTHER INFORMATION PLEASE CONTACT:

ALDA Pharmaceuticals Corp. Terrance G. Owen, Ph.D., MBA President, CEO and Director (604) 521-8300

or

ALDA Pharmaceuticals Corp. Peter Chen Distribution & Sales Contact (604) 521-8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacorp.com

or

ALDA Pharmaceuticals Corp. Scott Young Investor Relations Contact (604) 288-7222 Email: syoung@freeformcom.com Website: www.aldacorp.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.